The landscape for medical cannabis research in the United States is poised for significant transformation following a recent executive order by U.S. President Donald Trump, which aims to expedite the reclassification of cannabis under the U.S. Controlled Substances Act. This historic move, shifting cannabis from Schedule I to Schedule III, acknowledges its recognized medical utility and is expected to substantially reduce barriers to scientific inquiry and development within the sector. Companies in the pharmaceutical cannabinoid sector, such as MediPharm Labs Corp., a company specializing in precision-based cannabinoids, are part of the sector that may experience expanded opportunities, as a press release distributed via Yahoo Finance reported on December 20, 2025.
U.S. Cannabis Rescheduling and Regulatory Shift
President Trump’s executive order, issued on December 19, 2025, as detailed on the White House website, marks a pivotal moment for the medical cannabis industry. The reclassification from Schedule I to Schedule III is anticipated to streamline research protocols and foster greater collaboration between pharmaceutical companies and academic institutions.
This regulatory adjustment is expected to address long-standing challenges that have hindered comprehensive clinical trials in the U.S. By recognizing the medical applications of cannabis, the federal government aims to facilitate access to standardized, medical-grade cannabis for research purposes, a critical step for advancing evidence-based treatments.
Accelerating Medical Cannabis Research
The reclassification is projected to significantly accelerate medical cannabis research. President Trump stated in a White House statement that the order “will make it far easier to conduct marijuana-related medical research, allowing us to study benefits, potential dangers and future treatments.” Despite thousands of peer-reviewed cannabis studies published annually, full clinical trials have remained scarce due to the stringent restrictions imposed by Schedule I status and the lack of federally compliant cannabis.
The U.S. Food and Drug Administration (FDA) has already received more than 800 Investigational New Drug (IND) applications for cannabis-derived and cannabis-related products, as noted in a report in Exploration Pub. The shift to Schedule III is expected to unlock this pipeline, enabling researchers to more readily advance clinical trials and evaluate compliant active pharmaceutical ingredient (API) suppliers. Furthermore, this reclassification may lay the groundwork for future federally sanctioned medical access programs, mirroring existing frameworks in countries such as Canada, Australia, and Germany.
MediPharm Labs and Research Preparedness
MediPharm Labs has prepared for this evolving regulatory environment. According to the company, its extensive international licensing, U.S. clinical supply experience, and global regulatory expertise have been developed over several years, preparing it to serve the anticipated expansion of U.S.-based research.
Clinical Trial Experience
MediPharm has experience, having supplied product for over 10 active clinical trials. Notably, this includes the U.S. National Institutes of Health (NIH) funded LiBBY study with the Keck School of Medicine of University of Southern California. The company asserts that this was the first Phase 2 clinical trial of its kind to source API from a Canadian Licensed Producer, navigating the complexities of the prior Schedule I classification. MediPharm completed its initial shipment to the U.S. in 2023 and has made subsequent shipments, leveraging its FDA site registration and Drug Enforcement Administration (DEA) import permits.
Licensing and Certifications
The company highlights its unique combination of credentials, including a Drug Establishment License (DEL), Cannabis Drug License, Natural Health Product License, and both Good Manufacturing Practices (GMP) and EU-GMP certified operations. MediPharm was also the first FDA-audited purpose-built commercial cannabis facility in Canada, and one of only a handful globally. These certifications underscore its capacity to immediately support new research initiatives in the U.S. and internationally that demand pharmaceutical-grade standards for purity and consistency.
Investment Landscape for Pharmaceutical Cannabis
The reclassification of cannabis to Schedule III is also anticipated to impact the investment landscape. Institutional investors, previously constrained by ‘Schedule I trafficking’ clauses, may now be able to consider research-oriented cannabis companies. This regulatory evolution could lead to increased interest in pharmaceutical cannabis firms, including MediPharm Labs, and potentially renewed research investments from pharmaceutical companies that previously avoided the sector due to its high-risk classification.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
